GTCR, a leading private equity firm, announced today that its Cole-Parmer (“CP”) portfolio company has acquired ZeptoMetrix Corporation (“ZeptoMetrix”). ZeptoMetrix is a life sciences developer and manufacturer of quality control standards and verification panels used in molecular diagnostic testing for infectious diseases.
Founded in 1999 and headquartered in Buffalo, NY, ZeptoMetrix’s products, including its patented NATtrol™ family of products, are used for nucleic acid testing within the diagnostic testing industry. These products are used regularly by clinical testing labs to verify that molecular diagnostic instruments are performing and accurately detecting the presence of specific genetic material within a patient sample. The ZeptoMetrix product portfolio is focused on infectious disease, including gastrointestinal, women’s health, hospital acquired infections, and respiratory, including the flu, RSV and Covid, among others.
The acquisition of ZeptoMetrix expands CP’s quality controls and reference standards portfolio and further establishes CP as a leading manufacturer of specialty chemistries and reagents for life sciences research and diagnostic testing. The acquisition represents CP’s second acquisition in the past year and 12th since 2014.
“The addition of ZeptoMetrix is highly complementary to our existing product portfolio within the life sciences market,” said Bernd Brust, Chief Executive Officer of Cole-Parmer. “The acquisition underscores our dedication to serving our customers with unique, differentiated products that help accelerate their research & development programs and support their diagnostic workflows.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Dean Mihas, Managing Director at GTCR, added: “Cole-Parmer’s acquisition of ZeptoMetrix represents another great example of GTCR’s Leaders StrategyTM at work. Bernd and the CP team have completed 12 strategic add-on acquisitions since we carved the business out of Thermo Fisher and built a unique platform within the life sciences sector.”
“The addition of ZeptoMetrix to our global commercial infrastructure enhances our shared ability to continue to support our customers in mission critical applications within the life sciences,” added Jon Salkin, President of Cole-Parmer. “We look forward to continuing to support the ZeptoMetrix customer base and expanding our quality controls and reference standards portfolio via continued investment in organic product development and M&A.”
Source: Biospace
